Skip to main content
. 2020 Dec 14;9(6):369–379. doi: 10.4103/eus.eus_59_20

Table 4.

Summary of studies of EUS-biliary drainage versus ERCP

Author Study design Patients (n) Pathology Intervention Overall technical success rate, %(n) Overallbclinical success rate, %(n) Overall adverse events, %(n)
Dhir et al. (2015)[38] Retrospective, single centre 208 MDBO EUS BD (CDS/AS) versus ERCP 93.4 (97/104) versus 94.2 (98/104), P=0.246 89.4 (93/104) versus 91.3 (95/104), P=1.00 8.7 (9/104) versus 8.7 (9/104), P=1.00
Paik et al. (2018)[39] Prospective, Multicentre 125 MDBO EUS BD (HGS/CDS) versus ERCP 93.8 (60/64) versus 90.2 (55/61) 90 (54/60) versus 94.5 (52/55) 6.3 (4/64) versus 19.7 (12/61), P=0.03
Nakai et al. (2019)[40] Prospective, Multicentre with retrospective control group 34 MDBO EUS-CDS versus ERCP 97 (33/34) 100 (34/34) 15 (5/34) versus 24 (6/25), P=0.50
Park et al. (2018)[41] Prospective, single centre 30 MBO EUS-BD versus ERCP 92.8 (13/14) versus 100 (14/14), P=1.00 100 (13/13) versus 92.8 (13/14), P=1.00 0 versus 0

BD: Biliary drainage; CDS: Choledochoduodenostomy; HGS: Hepaticogastrostomy; MHBO: Malignant hilar biliary obstruction; MBO: Malignant biliary obstruction